India Cancer Drug Shortage Grows as Platinum Costs Surge

Indian pharmaceutical companies are halting production of essential chemotherapy drugs like cisplatin as global platinum prices rise from 2,000 to 5,000 rupees per gram. Manufacturers are calling for a 50% increase in government price caps to maintain supply chains and prevent further treatment disruptions.

Xurve View
洞察:

India is facing a critical shortage of platinum-based chemotherapy drugs as raw material costs jumped from 2,000 rupees to 5,000 rupees ($52.30) per gram. The supply crunch affects at least 25% of the nation's cancer patients who rely on these specific treatments for lung, liver, and ovarian malignancies. This crisis highlights the vulnerability of generic drugmakers to commodity price volatility when operating under strict government-mandated price ceilings.

### Supply Chain Disruptions and Rising Costs The shortage of cisplatin and carboplatin intensified over the last two weeks after South Africa exports slowed. Industry executives cited a combination of constrained mine output and Middle East conflict disruptions for the tightening supply. Platinum prices rallied to 5,000 rupees ($52.30) per gram, up from 2,000 rupees a year ago, according to Naprod Life Sciences director Mohan Jain.

IUX24

IUX24 提供深度財經、經濟與投資資訊,借助 AI 挖掘全球市場中最重要的訊號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場資料、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易訊號或經紀服務。投資涉及風險,使用者在做出投資決定前應審慎評估相關資訊。